FDA Accepts sNDA for Dermavant’s Vtama to Treat AD
The U.S. Food and Drug Administration (FDA) accepted Dermavant’s Supplemental New Drug Application (sNDA) for Vtama (tapinarof) cream, 1% for the topical treatment of atopic dermatitis (AD) in adults and children aged 2 and older. The Prescription Drug User Fee Act (PDUFA) action date assigned by the Agency is in Q4 2024. Vtama cream is a […]